Abstract
The cannabinoid receptor CB2 is highly expressed in immune cells suggesting an important role in numerous diseases such as inflammation, cancer, osteoporosis and liver diseases relating to modulation of the immune system. As a consequence, activation of receptor CB2 is a promising therapeutic strategy for the treatment of a large range of diseases. Indeed, selective CB2 agonists display beneficial anti-inflammatory, anti-cancer and antifibrogenic properties and positive effects on liver disease and osteoporosis. This article reviews the CB2 involvement in the immune system and the promising therapeutical potential of selective CB2 agonists in the treatment of several immune-related diseases.
Keywords: Analgesic, anticancer, antifibrogenic, anti-inflammatory, cannabinoid receptors, CB2 agonists, immune system, immune-related diseases, liver disease, osteoporosis.
Current Molecular Pharmacology
Title:Therapeutical Potential of CB2 Receptors in Immune-Related Diseases
Volume: 6
Author(s): Natascha Leleu-Chavain, Pierre Desreumaux, Philippe Chavatte and Regis Millet
Affiliation:
Keywords: Analgesic, anticancer, antifibrogenic, anti-inflammatory, cannabinoid receptors, CB2 agonists, immune system, immune-related diseases, liver disease, osteoporosis.
Abstract: The cannabinoid receptor CB2 is highly expressed in immune cells suggesting an important role in numerous diseases such as inflammation, cancer, osteoporosis and liver diseases relating to modulation of the immune system. As a consequence, activation of receptor CB2 is a promising therapeutic strategy for the treatment of a large range of diseases. Indeed, selective CB2 agonists display beneficial anti-inflammatory, anti-cancer and antifibrogenic properties and positive effects on liver disease and osteoporosis. This article reviews the CB2 involvement in the immune system and the promising therapeutical potential of selective CB2 agonists in the treatment of several immune-related diseases.
Export Options
About this article
Cite this article as:
Leleu-Chavain Natascha, Desreumaux Pierre, Chavatte Philippe and Millet Regis, Therapeutical Potential of CB2 Receptors in Immune-Related Diseases, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/1874467207666140219122337
DOI https://dx.doi.org/10.2174/1874467207666140219122337 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Chemoradiation for Glioblastoma
Current Drug Therapy Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Therapy Reviews Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Approaches for the Treatment of Glioblastoma)
Current Cancer Drug Targets Xanthones as Potential Antioxidants
Current Medicinal Chemistry Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Quantification of Rat Brain Amino Acids: Analysis of the Data Consistency
Current Analytical Chemistry The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Emerging Roles of microRNAs in Neural Stem Cells
Current Stem Cell Research & Therapy Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy